{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:18:03Z","timestamp":1788779883558,"version":"build-2803163510"},"reference-count":81,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Acyclovir is an antiviral drug effective against infections caused by herpes simplex and varicella zoster viruses. It is given intravenously to treat serious infections such as herpes encephalitis. High acyclovir concentrations could cause toxicity, observed mainly as nephrotoxicity and, to a lesser extent, neurotoxicity. Acyclovir nephrotoxicity is primarily attributed to the crystallization of acyclovir within the renal tubules, although additional mechanisms may also contribute. However, the mechanism of acyclovir-induced neurotoxicity is unknown. Acyclovir is mainly eliminated from the body through renal excretion; however, around 15\u201320% of acyclovir is metabolized subsequently by alcohol and aldehyde dehydrogenase to the main metabolite 9-carboxymethoxymethylguanine (CMMG), and around 2% is metabolized by aldehyde oxidase to the minor metabolite, 8-hydroxyl acyclovir. It has been suggested that CMMG levels above 10 \u00b5mol\/mL in the serum and 1 \u00b5mol\/mL in the cerebrospinal fluid are highly associated with neurotoxicity. Studies have shown that there is a potential contribution of CMMG to acyclovir-induced neurotoxicity and of the acyclovir aldehyde to nephrotoxicity. In this narrative review, we approach the topic of acyclovir metabolites and their association with acyclovir toxicity. Moreover, we identify the research gap of the mechanisms by which these metabolites contribute to toxicity.<\/jats:p>","DOI":"10.3390\/medicines13010006","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:12:37Z","timestamp":1770048757000},"page":"6","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Metabolites in Acyclovir-Induced Neurotoxicity and Nephrotoxicity"],"prefix":"10.3390","volume":"13","author":[{"given":"Asma","family":"Aboelezz","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-2622","authenticated-orcid":false,"given":"Sherif Hanafy","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jmv.1890410506","article-title":"Natural history, management and complications of herpes labialis","volume":"41","author":"Higgins","year":"1993","journal-title":"J. Med. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2006.04.002","article-title":"Herpes simplex encephalitis: Adolescents and adults","volume":"71","author":"Whitley","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/OLQ.0000000000001612","article-title":"Epidemiology of Herpes Simplex Virus Type 2 in Canada, Australia, and New Zealand: Systematic Review, Meta-Analyses, and Meta-Regressions","volume":"49","author":"AlMukdad","year":"2022","journal-title":"Sex. Transm. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4065\/84.3.274","article-title":"Herpes zoster (shingles) and postherpetic neuralgia","volume":"84","author":"Sampathkumar","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2024-056307","article-title":"Estimated global and regional incidence and prevalence of herpes simplex virus infections and genital ulcer disease in 2020: Mathematical modelling analyses","volume":"101","author":"Harfouche","year":"2025","journal-title":"Sex. Transm. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chaiyakunapruk, N., Lee, S.W.H., Kulchaitanaroaj, P., Rayanakorn, A., Lee, H., Looker, K.J., Hutubessy, R., and Gottlieb, S.L. (2024). Estimated global and regional economic burden of genital herpes simplex virus infection among 15\u201349 year-olds in 2016. BMC Glob Public Health, 2.","DOI":"10.1186\/s44263-024-00053-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM198601163140303","article-title":"Vidarabine versus acyclovir therapy in herpes simplex encephalitis","volume":"314","author":"Whitley","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e13622","DOI":"10.1111\/ctr.13622","article-title":"Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Pergam","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/272583a0","article-title":"9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group","volume":"272","author":"Schaeffer","year":"1978","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/j.1875-9114.1983.tb03274.x","article-title":"Acyclovir: Mechanism of action, pharmacokinetics, safety and clinical applications","volume":"3","author":"Gnann","year":"1983","journal-title":"Pharmacotherapy"},{"key":"ref_11","unstructured":"Schaechter, M. (2009). Antiviral Agents. Encyclopedia of Microbiology, Academic Press. [3rd ed.]."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0090-9556(25)08307-2","article-title":"Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys","volume":"22","author":"Burnette","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.1986.03370030107039","article-title":"Acyclovir therapy for herpes zoster: Advantages and adverse effects","volume":"255","author":"Balfour","year":"1986","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/01480540903311076","article-title":"Acute renal failure with acyclovir treatment in a child with leukemia","volume":"33","author":"Genc","year":"2010","journal-title":"Drug Chem. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1056\/NEJMicm066726","article-title":"Images in clinical medicine. Crystalluria from acyclovir use","volume":"358","author":"Mason","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00467-002-0867-5","article-title":"Combination of ceftriaxone and acyclovir\u2014An underestimated nephrotoxic potential?","volume":"17","author":"Vomiero","year":"2002","journal-title":"Pediatr. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.trsl.2011.07.002","article-title":"Acyclovir-induced nephrotoxicity: The role of the acyclovir aldehyde metabolite","volume":"158","author":"Gunness","year":"2011","journal-title":"Transl. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"113852","DOI":"10.1016\/j.biopha.2022.113852","article-title":"Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice","volume":"156","author":"Kacirova","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"111230","DOI":"10.1016\/j.jocn.2025.111230","article-title":"Acyclovir dosing strategies in herpes encephalitis: A retrospective charts review","volume":"136","author":"Aboelezz","year":"2025","journal-title":"J. Clin. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/ndt\/gfg119","article-title":"High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: An observational study","volume":"18","author":"Hellden","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0166-3542(82)90014-6","article-title":"Mode of action of acyclovir triphosphate on herpesviral and cellular DNA polymerases","volume":"2","author":"Allaudeen","year":"1982","journal-title":"Antivir. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","article-title":"Mechanism of action and selectivity of acyclovir","volume":"73","author":"Elion","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jnnp.63.3.321","article-title":"Herpes simplex encephalitis treated with acyclovir: Diagnosis and long term outcome","volume":"63","author":"McGrath","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_24","unstructured":"(2025, March 30). Acyclovir. Lexi-Drugs, Available online: https:\/\/online.lexi.com."},{"key":"ref_25","first-page":"518","article-title":"Evaluation of oral acyclovir therapy","volume":"19","author":"Fletcher","year":"1985","journal-title":"Drug Intell. Clin. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/09563202950060S609","article-title":"Valaciclovir\u2014A review of its potential in the management of genital herpes","volume":"6","author":"Crooks","year":"1995","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1006\/bbrc.1998.8628","article-title":"Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2","volume":"246","author":"Ganapathy","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.112.049239","article-title":"Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice","volume":"41","author":"Yang","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0090-9556(25)08307-2","article-title":"Metabolic disposition of the acyclovir prodrug valaciclovir in the rat","volume":"22","author":"Burnette","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/jac\/dkh244","article-title":"Pharmacokinetics of valaciclovir","volume":"53","author":"MacDougall","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/jmv.1890410529","article-title":"Valaciclovir (BW256U87): The L-valyl ester of acyclovir","volume":"41","author":"Jacobson","year":"1993","journal-title":"J. Med. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0002-9343(82)90094-8","article-title":"Metabolic fate of radioactive acyclovir in humans","volume":"73","author":"Good","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0002-9343(82)90089-4","article-title":"Acyclovir clinical pharmacology. An overview","volume":"73","author":"Lietman","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.21.5.804","article-title":"Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans","volume":"21","author":"Laskin","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00003088-198308030-00001","article-title":"Clinical pharmacokinetics of acyclovir","volume":"8","author":"Laskin","year":"1983","journal-title":"Clin. Pharmacokinet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1734-1140(13)71026-0","article-title":"Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3","volume":"65","author":"Ye","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1139\/y11-045","article-title":"Acyclovir is a substrate for the human breast cancer resistance protein (BCRP\/ABCG2): Implications for renal tubular transport and acyclovir-induced nephrotoxicity","volume":"89","author":"Gunness","year":"2011","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1479-5876-8-139","article-title":"The effect of acyclovir on the tubular secretion of creatinine in vitro","volume":"8","author":"Gunness","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"F767","DOI":"10.1152\/ajprenal.00312.2010","article-title":"Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates","volume":"299","author":"Shima","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/FPC.0000000000000305","article-title":"PharmGKB summary: Very important pharmacogene information for ABCG2","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet Genom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1128\/AAC.00729-09","article-title":"Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function","volume":"54","author":"Smith","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","article-title":"Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans","volume":"39","author":"Seaber","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jcpt.13464","article-title":"Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases","volume":"46","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nm0595-417","article-title":"Mitochondrial toxicity of antiviral drugs","volume":"1","author":"Lewis","year":"1995","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/10408440591002183","article-title":"Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health","volume":"35","author":"Siraki","year":"2005","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lu, H., Han, Y.J., Xu, J.D., Xing, W.M., and Chen, J. (2014). Proteomic characterization of acyclovir-induced nephrotoxicity in a mouse model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103185"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/03602532.2018.1555587","article-title":"Aldehyde toxicity and metabolism: The role of aldehyde dehydrogenases in detoxification, drug resistance and carcinogenesis","volume":"51","author":"Younus","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cvr\/cvq192","article-title":"Mitochondrial aldehyde dehydrogenase and cardiac diseases","volume":"88","author":"Chen","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/jac\/dkl067","article-title":"The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment","volume":"57","author":"Hellden","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11011-025-01694-8","article-title":"Neurotoxic effects of acyclovir: Impacts on oxidative stress, inflammation, and neurotransmitter dynamics in male Wistar rats","volume":"40","author":"Obembe","year":"2025","journal-title":"Metab. Brain Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jsps.2022.03.013","article-title":"Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity","volume":"30","author":"Falhammar","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/0886022X.2018.1487866","article-title":"The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration","volume":"40","author":"Lee","year":"2018","journal-title":"Ren. Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ofz121","DOI":"10.1093\/ofid\/ofz121","article-title":"Impact of Obesity on Acyclovir-Induced Nephrotoxicity","volume":"6","author":"Barber","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100046","DOI":"10.1016\/j.clinpr.2020.100046","article-title":"Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients?","volume":"7\u20138","author":"Sallevelt","year":"2020","journal-title":"Clin. Infect. Pract."},{"key":"ref_55","first-page":"e52367","article-title":"Acyclovir-Induced Nephrotoxicity and Neurotoxicity: A Report of Two Cases","volume":"16","author":"Lim","year":"2024","journal-title":"Cureus"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijid.2018.07.002","article-title":"Acute kidney injury (AKI) associated with intravenous aciclovir in adults: Incidence and risk factors in clinical practice","volume":"74","author":"Ryan","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2050313x20946518","DOI":"10.1177\/2050313X20946518","article-title":"Acyclovir-induced neurotoxicity in an immunocompromised patient","volume":"8","author":"Marks","year":"2020","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"bcr2013201941","DOI":"10.1136\/bcr-2013-201941","article-title":"Herpes zoster encephalopathy or acyclovir neurotoxicity: A management dilemma","volume":"2014","author":"Sacchetti","year":"2014","journal-title":"BMJ Case Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/infdis\/151.2.362","article-title":"Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster","volume":"151","author":"Bean","year":"1985","journal-title":"J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jcv.2014.09.001","article-title":"Aciclovir-induced neurotoxicity: Utility of CSF and serum CMMG levels in diagnosis","volume":"61","author":"Berry","year":"2014","journal-title":"J. Clin. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/ICB.0b013e3182252859","article-title":"Reversible mental status change and renal dysfunction associated with the use of high-dose oral valaciclovir therapy for acute retinal necrosis","volume":"6","author":"Lee","year":"2012","journal-title":"Retin. Cases Brief. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-4632.2007.03269.x","article-title":"Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient","volume":"46","author":"Yang","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.jemermed.2019.03.050","article-title":"Neurologic Acyclovir Toxicity in the Absence of Kidney Injury","volume":"57","author":"Patel","year":"2019","journal-title":"J. Emerg. Med."},{"key":"ref_64","first-page":"e92365","article-title":"Timely Diagnosis of Acyclovir-Induced Neurotoxicity During Acute Care Surgery Resuscitation: A Rare Complication of Common Herpes Zoster Treatment","volume":"17","author":"Ueno","year":"2025","journal-title":"Cureus"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/pn-2022-003597","article-title":"Aciclovir-induced neurotoxicity","volume":"23","author":"Vonberg","year":"2023","journal-title":"Pract. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1093\/jac\/dkz357","article-title":"An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: A prospective observational study","volume":"74","author":"Lindstrom","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bcp.13216","article-title":"The drugs that mostly frequently induce acute kidney injury: A case\u2014Noncase study of a pharmacovigilance database","volume":"83","author":"Gras","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102040","DOI":"10.1016\/j.japh.2024.02.013","article-title":"Acyclovir dosing in herpes encephalitis: A scoping review","volume":"64","author":"Aboelezz","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0002-9343(88)90313-0","article-title":"Acyclovir-induced renal failure. Clinical course and histology","volume":"84","author":"Sawyer","year":"1988","journal-title":"Am. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"agad077","DOI":"10.1093\/alcalc\/agad077","article-title":"Alcohol metabolism in alcohol use disorder: A potential therapeutic target","volume":"59","author":"Lehner","year":"2024","journal-title":"Alcohol. Alcohol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cld.2012.08.002","article-title":"Alcohol metabolism","volume":"16","author":"Cederbaum","year":"2012","journal-title":"Clin. Liver Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/pr.111.005538","article-title":"Aldehyde dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application","volume":"64","author":"Koppaka","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cbi.2012.11.016","article-title":"Inhibition of human alcohol and aldehyde dehydrogenases by cimetidine and assessment of its effects on ethanol metabolism","volume":"202","author":"Lai","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0003-9861(89)90416-5","article-title":"Role of extrahepatic alcohol dehydrogenase in rat ethanol metabolism","volume":"274","author":"Boleda","year":"1989","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2133\/dmpk.23.306","article-title":"Influence of ALDH2 genetic polymorphisms on aciclovir pharmacokinetics following oral administration of valaciclovir in Japanese end-stage renal disease patients","volume":"23","author":"Hara","year":"2008","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0002-9343(82)90087-0","article-title":"Renal function after acyclovir intravenous injection","volume":"73","author":"Brigden","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/1120009X.2016.1195070","article-title":"First case of herpetic meningoencephalitis treated with ganciclovir","volume":"29","author":"Blanc","year":"2017","journal-title":"J. Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.280.10.887","article-title":"Oral Famciclovir for the Suppression of Recurrent Genital HerpesA Randomized Controlled Trial","volume":"280","author":"Sibbald","year":"1998","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"gfae069-1110-3018","DOI":"10.1093\/ndt\/gfae069.1110","article-title":"Aciclovir or valaciclovir neurotoxicity in renal patients: Increasing number of neurotoxicity cases are diagnosed in Sweden by a blood test","volume":"39","author":"Hellden","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/jat\/bkae019","article-title":"Simultaneous analysis of acyclovir and its metabolite using hydrophilic interaction liquid chromatography-tandem mass spectrometry","volume":"48","author":"Takeda","year":"2024","journal-title":"J. Anal. Toxicol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/FTD.0b013e31828faa35","article-title":"Differential diagnosis of central nervous system involvement in a patient treated with acyclovir","volume":"35","author":"Axelsson","year":"2013","journal-title":"Ther. Drug Monit."}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/13\/1\/6\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:37:41Z","timestamp":1770050261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/13\/1\/6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicines13010006"],"URL":"https:\/\/doi.org\/10.3390\/medicines13010006","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}